Literature DB >> 8956348

An improved intercept method for the assessment of absorption rate in bioequivalence studies.

P Macheras1, M Symillides, C Reppas.   

Abstract

Mesh：

Year:  1996        PMID： 8956348     DOI： 10.1023/a:1016421630290

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  8 in total

1.  Sensitivity of empirical metrics of rate of absorption in bioequivalence studies.

Authors:  A Ring; L Tothfalusi; L Endrenyi; M Weiss
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

Review 2.  Measures of exposure versus measures of rate and extent of absorption.

Authors:  M L Chen; L Lesko; R L Williams
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Using partial area for evaluation of bioavailability and bioequivalence.

Authors:  Mei-Ling Chen; Barbara Davit; Robert Lionberger; Zakaria Wahba; Hae-Young Ahn; Lawrence X Yu
Journal:  Pharm Res       Date:  2011-04-13       Impact factor: 4.200

4.  The duration of measuring partial AUCs for the assessment of bioequivalence.

Authors:  L Endrenyi; F Csizmadia; L Tothfalusi; A H Balch; M L Chen
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

5.  Panos Macheras: a pioneering scientist in pharmaceutical science.

Authors:  Laszlo Endrenyi; Robert R Bies
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-03-28       Impact factor: 2.745

6.  The Two Main Goals of Bioequivalence Studies.

Authors:  Laszlo Endrenyi; Henning H Blume; Laszlo Tothfalusi
Journal:  AAPS J       Date:  2017-02-02       Impact factor: 4.009

7.  Metrics comparing simulated early concentration profiles for the determination of bioequivalence.

Authors:  L Endrenyi; F Csizmadia; L Tothfalusi; M L Chen
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

8.  The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms.

Authors:  Selma Sahin; Leslie Z Benet
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.